OXSORALEN-ULTRA
LOE ApproachingNDAORALCAPSULE
Approved
Oct 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OXSORALEN-ULTRA is an oral capsule formulation approved in 1986 for dermatological indications. The product mechanism of action and specific indications are not detailed in available data. It is an NDA-approved small molecule therapeutic.
LOE Approaching
With LOE approaching and no active clinical pipeline data, this mature product likely operates with a lean, maintenance-focused commercial team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OXSORALEN-ULTRA offers limited career growth due to LOE approaching status and zero linked job postings. This role is best suited for professionals seeking stable, operationally-focused positions in mature product management rather than innovation-driven advancement.
Product ManagerField Sales Representative
Worked on OXSORALEN-ULTRA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.